Table 4 Associations between circulating biomarkers of inflammation and overall mortality according to patients and tumour characteristics among all participants (n = 306).
HR (95% CI) | ||||||
---|---|---|---|---|---|---|
Characteristics | Event/total | CRPa | IL-6a | MCP-1a | Adiponectina | Leptina |
Overall | 94/306 | 1.32 (1.1–1.59) | 2.72 (2.07–3.56) | 1.97 (1.18–3.28) | 1.71 (1.14–2.58) | 0.85 (0.7–1.03) |
Sex | ||||||
Female | 42/157 | 1.28 (0.93–1.76) | 2.46 (1.61–3.76) | 2.33 (1.2–4.53) | 1.34 (0.77–2.34) | 0.69 (0.51–0.93) |
Male | 52/149 | 1.31 (1.03–1.65) | 3.17 (2.23–4.5) | 1.66 (0.69–3.98) | 2.31 (1.23–4.35) | 1 (0.76–1.32) |
Pinteraction | 0.82 | 0.54 | 0.72 | 0.24 | 0.11 | |
BMI | ||||||
Normal/Underweight | 31/101 | 1.76 (1.28–2.42) | 2.37 (1.6–3.53) | 1.89 (0.66–5.43) | 1.09 (0.46–2.59) | 0.81 (0.58–1.14) |
Overweight | 31/118 | 1.24 (0.9–1.72) | 4.22 (2.3–7.75) | 1.13 (0.33–3.95) | 1.79 (0.88–3.61) | 0.94 (0.65–1.37) |
Obese | 32/87 | 0.94 (0.63–1.41) | 2.3 (1.33–3.99) | 2.69 (1.27–5.69) | 2.08 (1.09–3.98) | 0.66 (0.45–0.97) |
Pinteraction | 0.02 | 0.13 | 0.94 | 0.37 | 0.82 | |
Smoking status | ||||||
Ever-smoker | 65/185 | 1.28 (1.03–1.59) | 2.41 (1.73–3.35) | 1.77 (0.98–3.2) | 1.73 (1.05–2.88) | 0.8 (0.64–1) |
Never-smoker | 29/121 | 1.52 (1.01–2.28) | 3.44 (1.92–6.15) | 2.65 (0.77–9.18) | 1.86 (0.86–4.02) | 0.86 (0.57–1.32) |
Pinteraction | 0.31 | 0.39 | 0.43 | 0.61 | 0.09 | |
Stage at diagnosis | ||||||
II | 42/143 | 1.3 (0.96–1.76) | 2.48 (1.57–3.92) | 1.44 (0.74–2.84) | 1.91 (1.04–3.5) | 0.88 (0.66–1.17) |
III | 52/163 | 1.35 (1.05–1.73) | 3.15 (2.18–4.56) | 2.53 (1.08–5.94) | 1.98 (1.09–3.62) | 0.78 (0.59–1.03) |
Pinteraction | 0.58 | 0.62 | 0.90 | 0.90 | 0.36 | |
KRAS mutation | ||||||
Mutant | 26/69 | 0.99 (0.65–1.52) | 1.89 (1.03–3.48) | 2.38 (0.4–14.16) | 1.85 (0.71–4.81) | 0.89 (0.59–1.33) |
Wild type | 52/181 | 1.54 (1.2–1.98) | 3.66 (2.35–5.69) | 1.72 (0.91–3.27) | 1.88 (1.11–3.2) | 0.75 (0.59–0.97) |
Pinteraction | 0.11 | 0.25 | 0.43 | 0.44 | 0.34 | |
BRAF mutation | ||||||
Mutant | 13/32 | 2.05 (1.11–3.8) | 10.23 (2.46–42.45) | 1.62 (0.25–10.6) | 1.97 (0.6–6.45) | 0.64 (0.36–1.15) |
Wild type | 66/222 | 1.24 (0.99–1.55) | 2.49 (1.73–3.58) | 1.8 (0.98–3.31) | 1.69 (1.04–2.74) | 0.85 (0.68–1.08) |
Pinteraction | 0.16 | 0.02 | 0.78 | 0.59 | 0.16 | |
MSI | ||||||
MSI-higha | 11/51 | 6.46 (2.04–20.49) | 17.47 (3.59–85.09) | 2.19 (0.39–12.47) | 1.63 (0.4–6.68) | 0.29 (0.13–0.68) |
MSS/MSI-low | 63/189 | 1.16 (0.92–1.47) | 1.94 (1.35–2.78) | 1.88 (1–3.51) | 1.74 (1.04–2.9) | 0.85 (0.68–1.08) |
Pinteraction | 0.007 | 0.02 | 0.47 | 0.63 | 0.02 | |
CIMP | ||||||
High | 17/41 | 1.25 (0.82–1.91) | 5.63 (2.04–15.57) | 3.56 (0.68–18.55) | 4.9 (1.41–17.02) | 0.4 (0.23–0.71) |
Low | 55/171 | 1.27 (0.99–1.63) | 2.64 (1.76–3.95) | 1.82 (0.96–3.47) | 1.48 (0.85–2.6) | 0.78 (0.6–1) |
Pinteraction | 0.52 | 0.23 | 0.64 | 0.32 | 0.06 | |
Surgeryb | ||||||
Yes | 79/284 | 1.36 (1.12–1.66) | 2.45 (1.82–3.3) | 1.91 (1.1–3.33) | 1.93 (1.26–2.98) | 0.78 (0.63–0.97) |
Pinteraction | – | – | – | – | – | |
Radiation | ||||||
Yes | 27/73 | 1.21 (0.91–1.61) | 1.9 (1.22–2.97) | 1.09 (0.33–3.56) | 1.54 (0.62–3.79) | 0.64 (0.44–0.92) |
No | 63/219 | 1.35 (1.07–1.71) | 3.1 (2.16–4.46) | 2.68 (1.32–5.44) | 1.67 (1.04–2.69) | 0.93 (0.72–1.19) |
Pinteraction | 0.33 | 0.07 | 0.18 | 0.35 | 0.03 | |
Chemotherapy | ||||||
Yes | 70/241 | 1.38 (1.12–1.7) | 2.89 (2.15–3.9) | 2.09 (1.19–3.68) | 1.47 (0.9–2.42) | 0.72 (0.56–0.91) |
No | 16/51 | 1.31 (0.83–2.08) | 1.37 (0.62–3.02) | 1.01 (0.23–4.47) | 5.29 (1.68–16.63) | 0.93 (0.56–1.57) |
Pinteraction | 0.39 | 0.44 | 0.52 | 0.34 | 0.39 | |
Tumour location | ||||||
Colom | 61/212 | 1.35 (1.06–1.71) | 3.36 (2.32–4.86) | 2.85 (1.66–4.87) | 1.67 (1.03–2.69) | 0.76 (0.6–0.97) |
Rectum | 32/93 | 1.21 (0.91–1.61) | 1.82 (1.17–2.83) | 0.35 (0.12–1.05) | 2.21 (1–4.85) | 0.9 (0.64–1.29) |
Pinteraction | 0.11 | 0.03 | 0.0005 | 0.20 | 0.21 |